Transparency Commission publishes its opinion for Kymriah

Transparency Commission

14 December 2018 - Opinion published following an examination of written submissions on 12 December 2018.

The Commission considers that Kymriah provides a moderate improvement in actual benefit (ASMR III) in the management strategy for children and young adults with refractory ALL, relapsing after transplant or after the second or subsequent relapse.

The Commission considers that, in the current state of the data, Kymriah provides an improvement in actual benefit (ASMR IV) in terms of efficacy compared to the historical management of refractory or relapsed diffuse large B-cell lymphoma, after at least two lines of systemic treatment, based on various chemotherapies.

Read Transparency Commission opinion (ALL) (French)

Read Transparency Commission opinion (NHL) (French)

Michael Wonder

Posted by:

Michael Wonder